Literature DB >> 26930926

[Diagnosis and treatment of schistosomiasis japonica-concensuses among ex- perts in Hunan, Hubei and Jiangxi provinces].

Wei-cheng Deng, Zhen Yang, Hui-qun Xie, Yong-long Li, Jia-xin Liu, Guo-jian Ding, Yong-hui Zhu, Qun-shan Jing, Guo-qing Kong, Dan-dan Lin, Jian-bing Liu, Guang-hui Ren.   

Abstract

In order to further standardize the diagnosis and treatment of schistosomiasis japonica in China, on the basis of evidence-based medicine, the experts on schistosomiasis control from Hunan, Hubei and Jiangxi provinces summarized their consensuses on the disease after the discussion on the current situation and progress of clinical diagnosis and treatment of schistosomiasis in China, with the reference to the Diagnostic Criteria for Schistosomiasis (WS261-2006), which aimed to establish the therapeutic standards or guideline of schistosomiasis in China.

Entities:  

Mesh:

Year:  2015        PMID: 26930926

Source DB:  PubMed          Journal:  Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi        ISSN: 1005-6661


  3 in total

1.  The soluble worm antigens-specific antibodies used as biomarkers of Schistosoma japonicum in a low prevalence and intensity endemic area of Hubei, China.

Authors:  Jianping Zhao; Xiaoping Chen; Xin Long; Nicholas Rafaels; Monica Campbell; Huifang Liang; Bixiang Zhang; Kathleen C Barnes; Robert G Hamilton; Qian Chen
Journal:  Acta Trop       Date:  2019-04-13       Impact factor: 3.222

2.  Derivation and external validation of a model to predict 2-year mortality risk of patients with advanced schistosomiasis after discharge.

Authors:  Guo Li; Shanshan Huang; Lifei Lian; Xiaoyan Song; Wenzhe Sun; Jinfeng Miao; Bohan Li; Yong Yuan; Shengfan Wu; Xiaoyan Liu; Zhou Zhu
Journal:  EBioMedicine       Date:  2019-08-23       Impact factor: 8.143

3.  Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis.

Authors:  Guo Li; Lifei Lian; Shanshan Huang; Jinfeng Miao; Huan Cao; Chengchao Zuo; Xiaoyan Liu; Zhou Zhu
Journal:  J Transl Med       Date:  2020-05-06       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.